^
BIOMARKER:

RRM2 overexpression

i
Other names: RRM2, Ribonucleotide Reductase Regulatory Subunit M2, Ribonucleoside-Diphosphate Reductase Subunit M2, Ribonucleotide Reductase M2 Polypeptide, Ribonucleotide Reductase Small Subunit, Ribonucleotide Reductase Small Chain, RR2, Chromosome 2 Open Reading Frame 48, Uncharacterized Protein C2orf48, FLJ25102, C2orf48, RR2M, R2
Entrez ID:
1m
LncRNA HOTAIR facilitates proliferation and represses apoptosis of retinoblastoma cells through the miR-20b-5p/RRM2/PI3K/AKT axis. (PubMed, Orphanet J Rare Dis)
LncRNA HOTAIR upregulated RRM2 by competitively binding to miR-20b-5p and activated PI3K/AKT pathway, thereby facilitating proliferation and repressing apoptosis of RB cells.
Journal
|
HOTAIR (HOX Transcript Antisense RNA) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • MIR20B (MicroRNA 20b)
|
RRM2 overexpression • miR-20b-5p expression
3ms
Ribonucleotide reductase subunit M2 promotes proliferation and epithelial-mesenchymal transition via the JAK2/STAT3 signaling pathway in retinoblastoma. (PubMed, Bioengineered)
Collectively, our data indicate that RRM2 promotes the progression of RB by activating JAK2/STAT3 signaling pathway. Targeting RRM2/JAK2/STAT3 axis lays a theoretical foundation for the formulation of novel RB therapy.
Journal
|
RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
RRM2 overexpression
4ms
RRM2 gene expression depends on BAF180 subunit of SWISNF chromatin remodeling complex and correlates with abundance of tumor infiltrating lymphocytes in ccRCC. (PubMed, Am J Cancer Res)
Furthermore, we show that exhausted CD4 T cells induced the expression of the RRM2 gene in the primary ccRCC cell line. Collectively, our results provide the link between PBRM1 loss, RRM2 expression and T cell infiltration, which may lead to the establishment of new treatment of this disease.
Journal • Tumor-Infiltrating Lymphocyte
|
PBRM1 (Polybromo 1) • CD4 (CD4 Molecule) • RRM1 (Ribonucleotide Reductase Catalytic Subunit M1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
PBRM1 mutation • RRM2 overexpression
5ms
piR-39980 mediates doxorubicin resistance in fibrosarcoma by regulating drug accumulation and DNA repair. (PubMed, Commun Biol)
Furthermore, overexpressing RRM2 induces DOX resistance of HT1080 cells by rescuing DOX-induced DNA damage by promoting DNA repair, whereas CYP1A2 confers resistance by decreasing intracellular DOX accumulation, which piR-39980 restores. This study reveals that piR-39980 could reduce fibrosarcoma resistance to DOX by modulating RRM2 and CYP1A2, implying that piRNA can be used in combination with DOX.
Journal
|
CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
RRM2 overexpression
|
doxorubicin hydrochloride
5ms
Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma. (PubMed, Gene)
Further, overexpression of RRM2 in HT1080 cells induces proliferation, migration, invasion, and colony formation, whereas its silencing arrest the cell cycle at G0/G1 phase and induces apoptosis. Taken together, we established RRM2 to be positively associated with oncogenesis and prognosis of STS and therefore could be a promising prognostic marker and therapeutic target.
Journal
|
RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
RRM2 overexpression
7ms
Journal
|
RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
RRM2 overexpression
11ms
Identification of Prognostic Related Hub Genes in Clear-Cell Renal Cell Carcinoma via Bioinformatical Analysis. (PubMed, Chin Med Sci J)
GEPIA Box Plot showed that BUB1, CCNB2, PTTG1, and RRM2 were over expressed in the ccRCC tissues in contrast to the normal tissues (P<0.05). Conclusion ccRCC patients with the four up-regulated differentially expressed genes including BUB1,CCNB2,PTTG1, and RRM2might manifest a poor prognosis.
Journal
|
PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1)
|
RRM2 overexpression
11ms
A Novel Signature of CCNF-Associated E3 Ligases Collaborate and Counter Each Other in Breast Cancer. (PubMed, Cancers (Basel))
Altogether, we propose a signature network of E3 ligases that collaboratively modulates CCNF anti-cancer activity. There is potential to target BRCA through modulation of the partnership axes of (i) CCNF-FBXL8, (ii) CCNF-FZR1, and (iii) CCNF-RRM2, particularly, via CCNF overexpression and activation and FBXL8/FZR1 suppression.
Journal • BRCA Biomarker
|
FBXW7 (F-Box And WD Repeat Domain Containing 7) • BRCA (Breast cancer early onset) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
RRM2 overexpression
1year
The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase. (PubMed, Clin Med Insights Oncol)
Our results show that the oncolytic effects of MYXV correlate directly with RR expression levels and are enhanced in STS cell lines with naturally occurring or artificially induced high expression levels of RR. Myxoma virus holds promise in the treatment of advanced soft tissue cancer, especially in tumors overexpressing RR.
Journal
|
RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
RRM2 overexpression
over1year
Targeting IGF perturbs global replication through ribonucleotide reductase dysfunction. (PubMed, Cancer Res)
This synthetic lethal effect reflected conversion of single-stranded lesions in IGF-inhibited cells into toxic DSBs upon ATM inhibition. Overall, these data implicate IGF-1R in alleviating replication stress, and the reciprocal IGF:ATM co-dependence we identify provides an approach to exploit this effect in ATM-deficient cancers.
Clinical • Journal
|
IGF1 (Insulin-like growth factor 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
RRM2 overexpression
over1year
Overexpression of RRM2 is related to poor prognosis in oral squamous cell carcinoma. (PubMed, Oral Dis)
Ribonucleotide reductase M2 may be a novel target in the diagnosis, prognosis, and therapy of OSCC.
Journal
|
CD44 • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
RRM2 overexpression
over1year
High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. (PubMed, Aging (Albany NY))
RRM2 over-expression increased the activation of Bcl-2 and E-cadherin signaling pathways, and reduced the activation of p53 signaling pathway. In summary, high RRM2 expression is an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
CDH1 expression • RRM2 overexpression
over1year
MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway. (PubMed, Mol Cell Biochem)
It was demonstrated that miR-20a suppressed NSCLC growth by inhibiting RRM2-mediated PI3K/Akt signaling pathway. These findings indicate that the novel identified miR-20a could function as a tumor suppressor in NSCLC through modulating the RRM2-mediated PI3K/Akt axis, and it could be a valid molecular target for NSCLC treatment.
Journal
|
RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
RRM2 overexpression